Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
P/E ratio for Zealand Pharma A/S (ZEAL.CO)
P/E ratio as of 2023: -30.01
According to Zealand Pharma A/S's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -30.01. At the end of 2022 the company had a P/E ratio of -9.64.
P/E ratio history for Zealand Pharma A/S from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -30.01 |
| 2022 | -9.64 |
| 2021 | -6.11 |
| 2020 | -10.00 |
| 2019 | -13.92 |
| 2018 | 4.38 |
| 2017 | -9.06 |
| 2016 | -16.82 |
| 2015 | -30.65 |
| 2014 | -28.90 |
| 2013 | -7.27 |
| 2012 | 53.50 |
| 2011 | 186.81 |
| 2010 | -12.17 |
| 2009 | -19.00 |
| 2008 | -45.08 |
| 2007 | -27.65 |